Insmed's brensocatib fails Phase 2b HS study; program discontinued

INSMED Inc

Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.
Secondary efficacy endpoints also not met; Insmed halts HS development of brensocatib.
Safety consistent with prior studies; no new signals; 40mg dose well tolerated.
Study enrolled 214 patients at 72 sites; 16-week placebo-controlled phase completed.
Topline results will be presented at a future medical congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.